Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JW-100 vs Eucrisa in Atopic Dermatitis
NCT05016284Phase 3Withdrawn
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Zygel in atopic dermatitis (AD) (2 arms). Primary endpoint: Success rate in Investigator's Static Global Assessment (ISGA) score at 15 days. Planned start Nov 2022; status: withdrawn.
02
Drugs
Zygel
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05016284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016284.